Synthesis and Molecular Docking Studies of Glucose-linked Isonicotinoyl- 1,3,4-Thiadiazolidines as Antitubercular Agents
作者:Snehal A. Chavan、Avinash G. Ulhe、Baliram N. Berad、Rupesh V. Chikhale
DOI:10.2174/1570178614666170608130326
日期:2017.12.11
Background: The recent emergence of multidrug-resistant strains of M. tuberculosis that are
resistant to two major effective drugs, viz. isoniazid and rifampicin, stimulated us to make an attempt
for the development of a new class of potent antitubercular agents by modifying the structures of existing
drugs. Aiming this, an efficient synthesis of glucose linked-isonicotinoyl-1,3,4-thiadiazolidines has
been carried out.
Method: The title compounds have been synthesized through cyclocondensation reaction of 1-
isonicotinoyl-4-aryl thiosemicarbazides with N-tetra-O-acetyl-β-D-glucopyranosyl isocyanodichloride.
The structures of newly synthesized compounds were verified by IR, 1H NMR, 13C NMR, mass spectrometry
and elemental analyses. The title compounds were evaluated for their in vitro antitubercular
potency against M. tuberculosis H37Rv strain using Lowenstein-Jensen method.
Results: A few title compounds were found to be equipotent with the reference drug rifampicin, while
moderately potent, when compared with the reference drug isoniazid. These compounds were subjected
to molecular docking studies and their results were found to be in agreement with the in vitro
studies.
Conclusion: We reported simple and efficient protocol for the synthesis of series of bioactive glucoselinked
isonicotinoyl-1,3,4-thiadiazolidines by utilizing N-tetra-O-acetyl-β-D-glucopyranosyl isocyanodichloride
as a suitable reagent for glycosylation. This approach is a valuable addition to the fastdeveloping
field of glucose-linked heterocycles and might be used to develop new potential drugs. We
demonstrated the introduction of isonicotinoyl and glucosyl moieties in single molecular framework
which may prove beneficial for developing new class of antitubercular agents.
背景:最近出现了对异烟肼和利福平这两种主要有效药物具有耐药性的结核杆菌耐多药菌株,这促使我们尝试通过改变现有药物的结构来开发一类新的强效抗结核药物。为此,我们进行了葡萄糖连接异烟酰基-1,3,4-噻二唑烷的高效合成。 方法:通过 1-异烟酰基-4-芳基硫代氨基甲酸与 N-四-O-乙酰基-β-D-吡喃葡萄糖基异氰基二氯的环缩合反应合成了标题化合物。 通过红外光谱、1H NMR、13C NMR、质谱和元素分析验证了新合成化合物的结构。采用 Lowenstein-Jensen 方法评估了标题化合物对结核杆菌 H37Rv 株的体外抗结核效力。 结果:发现一些标题化合物与参比药物利福平的效力相当,而与参比药物异烟肼相比,效力适中。对这些化合物进行了分子对接研究,发现其结果与体外研究结果一致。 结论:我们报道了利用 N-四-O-乙酰基-β-D-吡喃葡萄糖基异氰基二氯化物作为糖基化的合适试剂,合成一系列具有生物活性的葡萄糖苷联异烟酰基-1,3,4-噻二唑烷的简单而有效的方法。这种方法是对快速发展的葡萄糖连接杂环领域的宝贵补充,可用于开发新的潜在药物。我们展示了在单一分子框架中引入异烟酰基和葡萄糖基的方法,这可能会被证明有利于开发新型抗结核药物。